This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
Objective: To compare the onset and duration of sensory and motor block, haemodynamic responses, side effects associated with administration of thoracic epidural Levobupivacaine (0.5%) and Ropivacaine (0.5%) for modified radical mastectomy. Place and Duration of Study: Govt. Arignar Anna Memorial Cancer Hospital and Research Institute, Kanchipuram. 2023 - 24. Study Design: Randomized controlled clinical trial. Methodology: After obtaining approval from institutional ethics committee and written informed consent from all patients, a randomized controlled double blinded clinical trial was conducted on 30 ASA 3 carcinoma breast cases undergoing modified radical mastectomy. Patients were randomly allocated into two groups. Group L and Group R of 15 each. Patients in Group L were to receive Levobupivacaine 0.5% and Group R 0.5% Ropivacaine. Haemodynamic variables (heart rate, systolic and diastolic BP) and onset and duration of sensory and motor block, sensory regression time were recorded and compared using unpaired T-test. Conclusion: Levobupivacaine is better suited thoracic epidural anaesthetic drug for modified radical mastectomy surgeries than Ropivacaine.
Subramaniam S, Haribabu V. Comparison between levobupivacaine vs ropivacaine in thoracic epidural anaesthesia for modified radical mastectomy: a randomised controlled trial. Ind J Anesth Analg. 2025;12(3):171-175.
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
| Received | Accepted | Published |
|---|---|---|
| March 21, 2025 | May 31, 2025 | September 11, 2025 |
Monday 13 July 2026, 13:56:12 (IST)
Download citation
Highlight selected keywords in the article text.
| Received | March 21, 2025 |
| Accepted | May 31, 2025 |
| Published | September 11, 2025 |
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.